DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization
Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, today announced a strategic alliance to accelerate access to oncology clinical trials in Japan.
DURHAM, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets ...
Parexel, a CRO providing a full range of Phase I to IV clinical development services, and Partex, a digital pharma platform, entered a strategic alliance designed to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers, and to de-risk portfolio assets.
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the worlds largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Parexel Introduces Expert Series – New Medicines, Novel Insights